Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
Publication|Articles|July 27, 2026
- August 2026
- Volume 32
- Issue Spec 9
The Promise and Politics of Creating mRNA Vaccines in Cancer
Author(s)Ryan Flinn
Our August cover story from Evidence-Based Oncology.
Advertisement
Advertisement
In June, Moderna and Merck reported clinical trial follow-up results showing that their combination mRNA cancer vaccine and immunotherapy reduced the risk of melanoma recurrence in high-risk patients by nearly half over 5 years.1
Related to this article
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement